<DOC>
	<DOCNO>NCT01719263</DOCNO>
	<brief_summary>This study design demonstrate safety efficacy patient severe upper lobe predominant emphysema . For validity study , result compare patient receive optimal medical therapy .</brief_summary>
	<brief_title>Sequential Segmental Treatment Emphysema With Upper Lobe Predominance ( STEP-UP ) Study</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Heterogeneous emphysema upper lobe predominance lung FEV1 20 % 45 % predict Residual volume ( RV ) &gt; 150 % predict Postrehabilitation 6minute walk test &gt; 140 meter More 3 COPD related hospitalization require antibiotic past 12 month FEV1 &lt; 20 % predict DLCO &lt; 20 % predict immeasurable DLCO Body mass index ( BMI ) &lt; 18kg/m2 &gt; 32 kg/m2 History following : Left ventricular ejection fraction ( EF ) â‰¤ 40 % Stroke Myocardial infarction acute coronary syndrome previous year Hospitalization due leave ventricular failure previous 3 year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>emphysema</keyword>
	<keyword>InterVapor</keyword>
	<keyword>treatment</keyword>
	<keyword>pulmonary rehabilitation</keyword>
	<keyword>lung volume reduction</keyword>
	<keyword>endoscopic lung volume reduction</keyword>
</DOC>